Assenagon Asset Management S.A. Acquires New Stake in United Therapeutics Corporation (UTHR)

Assenagon Asset Management S.A. acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,282 shares of the biotechnology company’s stock, valued at approximately $426,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Ladenburg Thalmann Financial Services Inc. boosted its stake in United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock worth $104,000 after buying an additional 73 shares during the last quarter. Focused Wealth Management Inc boosted its stake in United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after buying an additional 140 shares during the last quarter. Advisory Services Network LLC purchased a new stake in United Therapeutics Corporation during the first quarter worth approximately $147,000. Daiwa Securities Group Inc. boosted its stake in United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after buying an additional 200 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in United Therapeutics Corporation during the first quarter worth approximately $204,000.

United Therapeutics Corporation (UTHR) traded down 1.298% during mid-day trading on Friday, hitting $129.655. 81,778 shares of the stock were exchanged. The company has a 50 day moving average price of $130.42 and a 200 day moving average price of $137.36. The firm has a market cap of $5.84 billion, a price-to-earnings ratio of 9.104 and a beta of 1.52. United Therapeutics Corporation has a 52-week low of $110.72 and a 52-week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share for the quarter, topping the consensus estimate of $3.12 by $0.77. The business had revenue of $370.50 million during the quarter, compared to the consensus estimate of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The company’s revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.02 EPS. On average, analysts anticipate that United Therapeutics Corporation will post $14.44 EPS for the current year.

United Therapeutics Corporation announced that its board has approved a stock repurchase plan on Thursday, April 27th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the biotechnology company to reacquire up to 4.6% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2017/07/21/assenagon-asset-management-s-a-acquires-new-stake-in-united-therapeutics-corporation-uthr.html.

UTHR has been the subject of a number of research analyst reports. UBS AG initiated coverage on shares of United Therapeutics Corporation in a report on Wednesday, March 29th. They issued a “sell” rating and a $112.00 price target for the company. Credit Suisse Group reaffirmed an “underperform” rating and issued a $120.00 price target on shares of United Therapeutics Corporation in a report on Monday, April 3rd. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a report on Monday, April 3rd. Cowen and Company cut shares of United Therapeutics Corporation from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $140.00 to $121.00 in a report on Monday, April 3rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $229.00 price target on shares of United Therapeutics Corporation in a report on Tuesday, April 4th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $134.50.

In related news, Director Christopher Causey sold 590 shares of the company’s stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $132.61, for a total value of $78,239.90. Following the completion of the sale, the director now owns 3,875 shares in the company, valued at approximately $513,863.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,234 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $132.32, for a total transaction of $163,282.88. Following the completion of the sale, the chief executive officer now owns 1,374 shares of the company’s stock, valued at approximately $181,807.68. The disclosure for this sale can be found here. Insiders have sold a total of 22,547 shares of company stock valued at $2,886,839 in the last 90 days. Insiders own 7.80% of the company’s stock.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply